Blauvelt, A.; Warren, R.; Reich, K.; al., et. Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated With Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin 2019, 3, 175.